Another study examined MSCs for treating GvHD in 10 patients and showed that mean plasma levels of interleukin 2 receptor alpha (IL-2Rα) and TNFR1 in acute GvHD patients before MSC infusion were high in responders and persistently decreased after MSC treatment [140]. The gene discussed is IL2RA; the disease is acute graft versus host disease.